Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities
Holders of notes who tendered, and did not validly withdraw, their notes on or before
Title of Security |
CUSIP No. |
Acceptance |
Reference |
Reference |
Fixed |
Total |
3.950% Notes due 2047 |
532457 BR8 |
1 |
2.875% due May 15, 2049 |
2.386% |
75 bps |
$1,147.59 |
3.700% Notes due 2045 |
532457 BJ6 |
2 |
2.875% due May 15, 2049 |
2.386% |
75 bps |
$1,096.72 |
3.875% Notes due 2039 |
532457 BS6 |
3 |
2.875% due May 15, 2049 |
2.386% |
57 bps |
$1,132.07 |
7.125% Notes due 2025 |
532457 AM0 |
4 |
1.500% due September 30, 2024 |
1.714% |
45 bps |
$1,258.72 |
6.77% Notes due 2036 |
532457 AP3 |
5 |
2.875% due May 15, 2049 |
2.386% |
75 bps |
$1,457.62 |
5.950% Notes due 2037 |
532457 BC1 |
6 |
2.875% due May 15, 2049 |
2.386% |
75 bps |
$1,385.12 |
5.55% Notes due 2037 |
532457 BA5 |
7 |
2.875% due May 15, 2049 |
2.386% |
70 bps |
$1,329.10 |
5.50% Notes due 2027 |
532457 AZ1 |
8 |
1.625% due August 15, 2029 |
1.907% |
45 bps |
$1,211.01 |
4.650% Notes due 2044 |
532457 BG2 |
9 |
2.875% due May 15, 2049 |
2.386% |
85 bps |
$1,235.36 |
3.100% Notes due 2027 |
532457 BP2 |
10 |
1.625% due August 15, 2029 |
1.907% |
35 bps |
$1,056.24 |
2.750% Notes due 2025 |
532457 BH0 |
11 |
1.50% due September 30, 2024 |
1.714% |
25 bps |
$1,039.49 |
3.375% Notes due 2029 |
532457 BV9 |
12 |
1.625% due August 15, 2029 |
1.907% |
60 bps |
$1,070.25 |
3.950% Notes due 2049 |
532457 BT4 |
13(3) |
2.875% due May 15, 2049 |
2.386% |
85 bps |
$1,133.22 |
4.150% Notes due 2059 |
532457 BU1 |
14(4) |
2.875% due May 15, 2049 |
2.386% |
105 bps |
$1,152.45 |
2.350% Notes due 2022 |
532457 BQ0 |
15(5) |
1.375% due October 15, 2022 |
1.679% |
20 bps |
$1,011.54 |
(1) Per $1,000 principal amount of notes that are tendered and accepted for purchase. |
(2) The total consideration includes the early tender premium of $30 per $1,000 principal amount of notes. |
(3) The maximum principal amount of 3.950% Notes due 2049 that will be purchased by Lilly is $200,000,000. |
(4) The maximum principal amount of 4.150% Notes due 2059 that will be purchased by Lilly is $200,000,000. |
(5) The maximum principal amount of 2.350% Notes due 2022 that will be purchased by Lilly is $250,000,000. |
All payments for notes purchased in connection with the early tender date will also include accrued and unpaid interest on the principal amount of notes tendered up to, but not including, the initial settlement date, which is currently expected to be
Holders of notes who validly tender their notes after the early tender date will, if such notes are accepted by Lilly, receive the tender consideration, which is equal to the total consideration minus
The tender offer is scheduled to expire at 11:59 p.m.,
In accordance with the terms of the tender offer, the withdrawal date was
The tender offer is being conducted upon the terms and subject to the conditions set forth in the Offer to Purchase, dated
Lilly has retained
Requests for documents relating to the tender offer may be directed to
This press release is for informational purposes only and is not a tender offer to purchase or a solicitation of acceptance of a tender offer, which may be made only pursuant to the terms of the Offer to Purchase. In any jurisdiction where the laws require the tender offer to be made by a licensed broker or dealer, the tender offer will be deemed made on behalf of Lilly by the dealer managers, or one or more registered brokers or dealers under the laws of such jurisdiction. In addition, this press release is not an offer to sell or the solicitation of an offer to buy any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any such securities will be offered only by means of a prospectus, including a prospectus supplement relating to such securities, meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. F-LLY
This press release contains management's current intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "expect", "believe", "target" and similar expressions are intended to identify forward-looking statements, including but not limited to statements about the terms and conditions of, and the completion of, the tender offer. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the control of Lilly, that may cause its actual results to differ materially from those indicated in its forward-looking statements. For a further discussion of these risks and uncertainties, please see Lilly's latest Form 10-K and subsequent filings with the
Refer to: Mark Taylor; mark.taylor@lilly.com; (317) 276-5795 (Media)
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-announces-the-pricing-terms-of-its-cash-tender-offer-for-up-to-2-000-006-000-aggregate-principal-amount-of-its-outstanding-debt-securities-300954097.html
SOURCE